Galenica <GALN.S> has agreed to buy Relypsa <RLYP.O> for $1.53 billion, paying a big premium for the Californian biotech company to strengthen its Vifor Pharma unit ahead of splitting up the Swiss ...

Galenica has agreed to buy U.S. biotech firm Relypsa for $1.53 billion in cash to strengthen its Vifor Pharma unit ahead of splitting up the Swiss healthcare group. Galenica, which owns ...

Galenica plans to split its pharmaceutical and health-care operations into two separate businesses, a first step toward potential listings of each as independent companies.

That couldn’t have hurt Relypsa’s chances to sell itself at a good price--and now, the specialty pharma Galenica has snapped up the California-based drugmaker in a $1.53 billion cash deal.

Galenica Group has agreed to acquire Relypsa for about $1.53 billion, the companies said today, in a deal designed to strengthen the buyer’s Vifor Pharma unit with a dedicated U.S. commercial ...

The board of Galenica AG has announced that it will be paying its dividend of CHF2.30 on the 16th of April, an increased payment from last year's comparable dividend. This will ...

Please use one of the following formats to cite this article in your essay, paper or report: APA. CSL Ltd. (2019, June 20). Galenica Group focuses on pharmaceuticals as it becomes Vifor Pharma Group.

Galenica AG / Key word(s): Annual Results11-March-2025 / 06:45 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this ...

Galenica AG, the owner of Switzerland’s biggest pharmacy network, may list its Vifor Pharma unit earlier than planned, Chairman Etienne Jornod said.

Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million. As a result, Galenica outperformed the entire pharmaceutical market in terms of growth ...

Galenica Sante's <GALE.S> shares rose more than 10 percent in their stock market debut on Friday, after the largest Swiss pharmacy retailer raised 1.9 billion Swiss francs ($1.9 billion) in Europe ...

The Galenica Group enjoys a leading position in all its areas of activity - pharmaceutical manufacturing, pre-wholesaling, distribution, healthcare information and retailing.